PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

NEXT STORY
Analytics for Risk Contracting, LLC Expands Client Portfolio with the Addition of Sendero Health Plans
PREV STORY
Athenex Provides a Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Trillium Therapeutics Joins Russell 2000® and 3000® Indices

author_avatar
NASDAQ Market News

GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

author_avatar
NASDAQ Market News

European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

author_avatar
NASDAQ Market News